Publications Database

High-resolution (7T) MRI facilitates in vivo imaging of fine anatomical structures selectively affected in Alzheimer's disease (AD), including medial temporal lobe subregions. However, 7T data is challenging to acquire and largely unavailable in clinical settings. [...]

Tau accumulation drives neurodegeneration and cognitive decline in Alzheimer's Disease (AD) and preclinical research suggests that tau spreads transsynaptically across connected neurons. We translated tau spreading models to human neuroimaging data, showing that tau pathology spreads from circumscribed epicenters to connected regions in AD, following the architecture of functional brain networks. [...]

While aging almost inevitably leads to some degree of cognitive decline, the interindividual heterogeneity in the trajectories of decline raises the question of the extent to which resistance against pathology and cognitive resilience are involved. Using a multimodal approach including neuroimaging, fitness assessment, questionnaire data, and Alzheimer's disease (AD) genetic risk and plasma biomarkers (Figure 1), we aimed to characterize latent structures of lifestyle, mental and bodily health, estimate indices of brain (pathological) and cognitive aging, and relate lifestyle/health profiles and AD genetic risk to these indices.We analyzed a subsample of 211 cognitively normal older adults aged ≥ 60 years from an ongoing study (CRC1436) (age=71.0±7.4years, 46% female). [...]

The nucleus basalis of Meynert (NBM) is crucial for learning, attention, and memory. While its involvement in Alzheimer's disease (AD) has been widely reported, the role in frontotemporal dementia (FTD) remains unclear. [...]

With the approval of anti-amyloid therapies in Alzheimer's disease (AD), surrogate biomarkers are urgently needed to monitor treatment effects that translate into clinical benefits. Candidate biomarkers, including amyloid-PET, tau-PET, plasma phosphorylated tau (p-tau), and MRI-assessed atrophy, capture core pathophysiological changes in AD. [...]

Genome-wide association studies (GWAS) have identified a larger number of genetic variants that are associated with increased risk of AD dementia. The biological pathways that underlie the link between SNPs and the development of core AD pathologies remain however unclear. [...]

Alzheimer's Disease (AD) pathology accumulates early in the medial temporal lobe (MTL), crucial for spatial navigation. As spatial navigation is among the first cognitive functions affected by AD, it may benefit from targeted behavioral interventions. [...]

Traditional pen-and-paper neuropsychological assessments are not sensitive to subtle cognitive changes in the earliest stages of Alzheimer's disease (AD), limiting their use for monitoring of cognitive performance over shorter timeframes. Here, we show that frequently administered remote and unsupervised digital cognitive assessments are better suited to capture short-term cognitive decline in early AD.We investigated episodic memory trajectories using self-administered remote digital testing in 202 participants (52-85 years) who completed unsupervised tests for at least 30 weeks. [...]

Neuroinflammation is central to Alzheimer's disease (AD) pathogenesis, yet its contribution to region-specific brain atrophy remains unclear. We examined whether cerebrospinal fluid (CSF) biomarkers predict longitudinal atrophy in the hippocampus and basal forebrain and mediate the impact of AD pathology.Data from 227 DELCODE participants with baseline CSF measures and longitudinal structural MRI were analyzed. [...]

Microbiome-based therapies are promising new treatment avenues. While global alterations in microbiota composition have been shown in multiple sclerosis, whether and how gut microbiota influence autoimmune responses in an antigen-specific manner is unclear. [...]